Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=195 Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation
Ischemic Stroke · Transient Ischemic Attack
Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants
N/A N=72 Metacognitive-Strategy Training in Sub-Acute Stroke
Stroke
Primary: Canadian Occupational Performance Measure (COPM) — 3.77; 3.87 score on a scale — p=.693
N/A N=20 Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke
Stroke
Primary: Change in Corticomotor Excitability — 0.38; 0.37; 0.41; 0.37 millivolt (mV)
Phase 3 N=20 Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
Coronary Artery Disease · Acute Myocardial Ischemia
Primary: Left Ventricular Global Strain Rate — 18; 23 percentage of change
Phase 4 N=543 EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
Cerebrovascular Accident
Primary: Telephone Modified Rankin Scale (Centralised, Blinded Assessment) — 58; 70; 75; 84 participants — p=0.683
N/A N=4 Treatment of Hand Dysfunction After Stroke
Stroke
Primary: Fugl-Meyer Upper Limb Coordination Scale (FMUE) — 27.75; 48.50 units on a scale — p=.0001
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
Phase 2 N=18 Positional Therapy After Stroke
Sleep Apnea · Stroke
Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
N/A N=58 Stimulating Language in Subacute StrokE
Stroke
Primary: Change in Accuracy of Naming Untrained Pictures (Philadelphia Naming Test (PNT)) Pre-treatment to 1 Week Post-treatment — 22.3; 18.5 score on a scale — p=0.54
Phase 2 N=3 Histamine Glutamate Antagonism in Stroke
Acute Cerebrovascular Accident · Cerebral Edema
Primary: Modified Rankin Score
Phase 2 N=121 A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Analysis of the National Institutes of Health Stroke Scale (NIHSS) Total Score Area Under the Curve During the Treatment Period — 3.83; 3.13 units on a scale
N/A N=11 Primed vs. Unprimed rTMS in Chronic Stroke
Stroke
Primary: Change in Cortical Excitability: Paired-Pulse — -18; 18; 12 milivolt
N/A N=92 Frequency vs Error Augmentation Training in Acute Physical Therapy Post Stroke
Stroke · Stroke, Acute · Stroke, Ischemic
Primary: Change in Postural Assessment Stroke Scale (PASS) — 19.64; 19.86; 19.25; 23.21 score on a scale
N/A N=10 Pilot of Cognitive Stimulation Therapy for Pre-frail Stroke Survivors
Stroke · Frailty · Carers
Primary: Framework Analysis Using the Theoretical Framework of Acceptability as a Guiding Framework — 4; 4; 4; 4 Participants